

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**RLL-292US**

In Re Application Of: **MEHTA et al.**

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------|----------|--------------|----------------|------------------|
| 10/552,617      | 04/10/03    | TBA      | 26,815       | TBA            | 6306             |

Title:

**SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

Address to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
  - the statement specified in 37 CFR 1.97(e);

**OR**

- the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**RLL-292US**

In Re Application of: **MEHTA et al.**

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------|----------|--------------|----------------|------------------|
| 10/552,617      | 04/10/03    | TBA      | 26,815       | TBA            | 6306             |

Title:

**SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \_\_\_\_\_ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.

Charge the amount of \_\_\_\_\_  
 Credit any overpayment.  
 Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
 (Date)

\_\_\_\_\_  
 Signature

\_\_\_\_\_  
 Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on \_\_\_\_\_

\_\_\_\_\_  
 (Date)

\_\_\_\_\_  
 Signature of Person Mailing Correspondence

\_\_\_\_\_  
 Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
 Signature

Dated: **March 19, 2007**

Kenneth Y. Lo, Reg. No. 51,961  
 Customer No. 26,815  
 Ranbaxy Inc.  
 600 College Road East, Suite 2100  
 Princeton, NJ 08540

CC:

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: MEHTA *et al.*

Application No.: 10/552,617

Filing Date: TBA

Title: SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS  
MUSCARINIC RECEPTOR ANTAGONISTS

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that the following correspondence:

- Transmittal Letter to the US/DO/EO Concerning a Filing Under 35 USC 371
- Transmittal of Information Disclosure Statement
- Information Disclosure Citation with references
- Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 19, 2007.

Susan Dolci  
Name of Person Mailing Correspondence

Susan Dolci  
Signature

EV 919465093 US  
"Express Mail" Mailing Label Number

|                                 |  |  |                                 |                        |
|---------------------------------|--|--|---------------------------------|------------------------|
| INFORMATION DISCLOSURE CITATION |  |  | Docket No.: RLL-292US           | Serial No.: 10/552,617 |
|                                 |  |  | Applicants: MEHTA <i>et al.</i> |                        |
|                                 |  |  | Filed: 10/6/2005                | Group:                 |

### U.S. PATENT DOCUMENTS

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE       | NAME                   | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|----|-----------------|------------|------------------------|-------|----------|----------------------------|
|                  | A1 | 3,176,019       | 3/30/1965  | Campbell <i>et al.</i> | 260   | 293.4    |                            |
|                  | A2 | 5,281,601       | 1/25/1994  | Cross <i>et al.</i>    | 514   | 320      |                            |
|                  | A3 | 5,948,792       | 9/7/1999   | Tsuchiya <i>et al.</i> | 514   | 317      |                            |
|                  | A4 | 6,130,232       | 10/10/2000 | Mase <i>et al.</i>     | 514   | 318      |                            |
|                  | A5 | 6,174,900       | 1/16/2001  | Okada <i>et al.</i>    | 514   | 317      |                            |
|                  | A6 | 6,307,060       | 10/23/2001 | Noe <i>et al.</i>      | 548   | 551      |                            |

### FOREIGN PATENT DOCUMENTS

|  |     | DOCUMENT NUMBER | DATE       | COUNTRY | CLASS | SUBCLASS | TRANSLATION<br>YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> |
|--|-----|-----------------|------------|---------|-------|----------|--|
|  | B1  | EP 0 325 571    | 7/26/1989  | EPO     | C07C  | 215/54   | <input checked="" type="checkbox"/>  |
|  | B2  | EP 0 388 054    | 9/19/1990  | EPO     | C07D  | 207/08   | <input checked="" type="checkbox"/>  |
|  | B3  | EP 0 413 455    | 2/20/1991  | EPO     | C07D  | 401/04   | <input checked="" type="checkbox"/>  |
|  | B4  | EP 0 801 067    | 10/15/1997 | EPO     | C07D  | 453/02   | <input checked="" type="checkbox"/>  |
|  | B5  | EP 0 863 141    | 9/9/1998   | EPO     | C07D  | 401/06   | <input checked="" type="checkbox"/>  |
|  | B6  | GB 940,540      | 10/30/1963 | UK      | C07C  |          | <input checked="" type="checkbox"/>  |
|  | B7  | JP 135958/1994  | 5/17/1994  | Japan   | C07D  | 333/16   | <input checked="" type="checkbox"/>  |
|  | B8  | JP 92921/1994   | 4/5/1994   | Japan   | C07C  | 237/20   | <input checked="" type="checkbox"/>  |
|  | B9  | WO 91/09013     | 6/27/1991  | PCT     | C07D  | 207/08   | <input checked="" type="checkbox"/>  |
|  | B10 | WO 93/16018     | 8/19/1993  | PCT     | C05F  | 17/02    | <input checked="" type="checkbox"/>  |
|  | B11 | WO 93/16048     | 8/19/1993  | PCT     | C07D  | 211/26   | <input checked="" type="checkbox"/>  |
|  | B12 | WO 96/33973     | 10/31/1996 | PCT     | C07D  | 211/46   | <input checked="" type="checkbox"/>  |
|  | B13 | WO 97/45414     | 12/4/1997  | PCT     | C07D  | 211/58   | <input checked="" type="checkbox"/>  |
|  | B14 | WO 98/05641     | 2/12/1998  | PCT     | C07D  | 211/46   | <input checked="" type="checkbox"/>  |
|  | B15 | WO 98/29402     | 7/9/1998   | PCT     | C07D  | 311/20   | <input checked="" type="checkbox"/>  |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |

|  |                                 |                        |
|--|---------------------------------|------------------------|
| <b>INFORMATION DISCLOSURE CITATION</b> | Docket No.: RLL-292US           | Serial No.: 10/552,617 |
|  | Applicants: MEHTA <i>et al.</i> |                        |
|  | Filed: 10/6/2005                | Group:                 |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|     |  |
|-----|--|
| C1  | Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)   |
| C2  | Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)  |
| C3  | Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)   |
| C4  | Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)  |
| C5  | Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)   |
| C6  | Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)  |
| C7  | Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)   |
| C8  | de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)   |
| C9  | Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282   |
| C10 | Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)   |
| C11 | Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)                  |
| C12 | Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :984-987 (2002)                     |
| C13 | Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", <i>Journal of the American Chemical Society</i> , <u>75</u> :2654-2657 (1953)  |
| C14 | Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999) |
| C15 | Cheng and Prusoff, "Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)      |
|     |  |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |